Table_2_Characterization of Pseudomonas aeruginosa Bacteriophage L5 Which Requires Type IV Pili for Infection.docx

Pseudomonas aeruginosa is a common opportunistic human pathogen. With the emergence of multidrug-resistant (MDR) clinical infection of P. aeruginosa, phage therapy has received renewed attention in treating P. aeruginosa infections. Moreover, a detailed understanding of the host receptor of lytic phage is crucial for selecting proper phages for therapy. Here, we describe the characterization of the P. aeruginosa bacteriophage L5 with a double-stranded DNA genome of 42,925 bp. The genomic characteristics indicate that L5 is a lytic bacteriophage belonging to the subfamily Autographivirinae. In addition, the phage receptors for L5 were also identified as type IV pili, because the mutation of pilZ, which is involved in pili synthesis, resists phage infection, while the complementation of pilZ restored its phage sensitivity. This research reveals that L5 is a potential phage therapy candidate for the treatment of P. aeruginosa infection.

铜绿假单胞菌（Pseudomonas aeruginosa）是一种常见的人类条件致病菌。随着铜绿假单胞菌多重耐药（multidrug-resistant, MDR）临床感染的出现，噬菌体疗法在治疗该菌感染方面重新受到关注。此外，深入解析裂解性噬菌体的宿主受体，对于筛选适配的治疗用噬菌体至关重要。本研究对铜绿假单胞菌噬菌体L5进行了表征，其基因组为双链DNA，长度为42925 bp。基因组特征表明，L5是隶属于自噬噬菌体亚科（Autographivirinae）的裂解性噬菌体。此外，本研究还鉴定出L5的噬菌体受体为IV型菌毛（type IV pili）：参与菌毛合成的pilZ基因突变后，宿主菌株可抵抗噬菌体感染；而通过互补恢复pilZ表达后，菌株重新获得了噬菌体敏感性。本研究揭示，L5是用于治疗铜绿假单胞菌感染的潜在噬菌体疗法候选剂。